Investor Presentation Full Year 2021

27 Investor presentation Full year 2021 Insulin sales remain important with more than 39% share of revenue but with less dependence on the US insulin sales 44% Q4 2016 sales split IO: International Operations; NAO: North American Operations 26% 30% Q4 2021 sales split 28% 61% 11% IO insulin NAO insulin Other products Novo NordiskⓇ

View entire presentation